We found that compared with normal‐weight breast cancer patients, serum vaspin levels in overweight patients were significantly increased, and vaspin could promote the progression of triple‐negative breast cancer by regulating the miR‐33a‐5p/ABHD2 pathway. Here, ABHD2 is linked to breast carcinoma.